Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Sphingosine-1-phosphate receptor modulators

6 evidence topics · 6 sources

Mechanism and pivotal trial results: ACG 2025 evidence summary

“The small molecule S1P receptor modulators ozanimod and etrasimod have a mechanism of action that sequesters activated lymphocytes in lymph nodes in patients with UC and results in decreased cellular inflammation in the bowel and a corresponding decreased circulating lymphocyte count.” (opens the source at this quote in a new tab)

“At the end of 10 weeks, a larger proportion of patients receiving ozanimod achieved clinical remission (18.4%) compared with placebo (6.0%, P < 0.001)).” (opens the source at this quote in a new tab)

“At the end of the maintenance period, 37% of patients continuing ozanimod achieved clinical remission compared with 18.5% of patients receiving placebo (P < 0.001).” (opens the source at this quote in a new tab)

“In the ELEVATE UC 52 study, at the completion of 12 and 52 weeks of treatment, 27% and 32% of patients receiving etrasimod achieved clinical remission compared with 7% and 7% of patients treated with placebo (P < 0.0001 for both comparisons).” (opens the source at this quote in a new tab)

“Unlike all other modern pivotal trials for moderately to severely active UC which excluded patients with isolated proctitis, the pivotal trials for etrasimod included patients with isolated proctitis and demonstrated a clinical remission rate in these patients of 43.2% at week 12, compared with 13.6% with placebo (P < 0.001).” (opens the source at this quote in a new tab)

“Significant cardiovascular disease, severe untreated sleep apnea, cardiac conduction defects, and concomitant use of monoamine oxidase inhibitors contraindicate the use of ozanimod.” (opens the source at this quote in a new tab)